GIPR and obesity due to melanocortin 4 receptor deficiency: Among these, tirzepatide, a long-acting dual GLP-1R/GIPR agonist approved for diabetes and obesity, shows enhanced therapeutic outcomes on cardiometabolic diseases compared to selective GLP-1R agonists.20